Key Insights

Highlights

Treatment Research

2 treatments under study, led by Fosmanogepix

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT06925321Phase 3Recruiting

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.

Showing all 1 trials

Research Network

Common Treatments

  • Fosmanogepix1
  • Standard Of Care Antifungal Therapy1

Active Sponsors

  • Biomedical Advanced Research and Development Authority1
  • Basilea Pharmaceutica International AG Allschwil1
  • Basilea Pharmaceutica1

Top Investigators

Related Conditions

  • Invasive Mold Infections1

Activity Timeline